Nov 8, 2025
(via Antimetabolites - Mechanism, Examples, and Clinical Uses)
seen from Poland
seen from Netherlands
seen from United States
seen from United States
seen from Germany
seen from China
seen from China
seen from United States
seen from United Kingdom
seen from Netherlands
seen from Netherlands
seen from T1
seen from Canada
seen from United States
seen from France
seen from Kazakhstan
seen from United Kingdom
seen from Italy
seen from China
seen from China
(via Antimetabolites - Mechanism, Examples, and Clinical Uses)
Pemetrexed Market Market 2021 2026 Straits Research has recently added a new report to its vast depository titled Global Pemetrexed Market Market The report studies vital factors about the Global Pemetrexed Market Market that are essential to be understood by ...
Thuốc Alimta 500mg là gì? Thuốc Alimta 500mg là thuốc ETC dùng trong điều trị u trung biểu mô màng phổi ác tính không thể cắt bỏ chưa được dùng hóa trị liệu. Tên biệt dược Alimta 500mg Dạng trình bày Thuốc Alimta 500mg được bào chế dưới dạng bột đông khô pha dung dịch tiêm […] Bài viết Thuốc Alimta 500mg: Liều dùng & lưu ý, hướng dẫn sử dụng, tác dụng phụ đã xuất hiện đầu tiên vào ngày Medplus.vn .
Global Pemetrexed Market was valued at approximately 2,062 million in 2017. According to the National Cancer Institute, 228,150 new cases of lung cancer are estimated to be registered in the U.S. by the end of 2019.
North America dominated the global pemetrexed market in 2018 and is expected to continue the same during the forecast period 2019–2026. The prevalence of lung cancer patients in the U.S. is increasing rapidly as result of increasing pollution level, changing lifestyle, and constantly increasing demand for pemetrexed in the U.S. oncology market due to the high efficiency of the drug.
Pemetrexed Market 2018-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2458
Approval and Launch of Affordable Generic of Pemetrexed in Market is Expected to Increase its Adoption
Alimta is a patented drug of Eli Lilly and Company and is protected by a vitamin regimen patent (2021), and pediatric exclusivity (2022) in the U.S., vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan.
However, Eli Lilly and Company’s compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015.
Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
Furthermore, Eli Lilly and Company is dedicated in frequent research and development in order to expand the indication of Alimta and to generate high revenue benefits.
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.
Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458
Pemetrexed Market 2018 Industry Analysis, Top Company, Research Forecast, Analysis and Supply Demand Report 2026 : United States
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2458
Approval and Launch of Affordable Generic of Pemetrexed in Market is Expected to Increase its Adoption
Alimta is a patented drug of Eli Lilly and Company and is protected by a vitamin regimen patent (2021), and pediatric exclusivity (2022) in the U.S., vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan.
However, Eli Lilly and Company’s compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015.
Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
Furthermore, Eli Lilly and Company is dedicated in frequent research and development in order to expand the indication of Alimta and to generate high revenue benefits.
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.
Pemetrexed - a folate antimetabolites chemotherapy medication which inhibits thymidylate synthase, dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) enzymes used in purine and pyrimidine synthesis, hence formation of RNA and DNA. It is used for the treatment of non-small cell lung carcinoma, and pleural mesothelioma.
Promising New Drug Attacks Cancer Stem Cells in Mesothelioma
Promising New Drug Attacks Cancer Stem Cells in Mesothelioma
The anticancer drug defactnib is currently the subject of clinical trials being conducted in multiple countries. Data from this trial in patients with a type of cancer called mesothelioma has shown that defactnib is potentially quite effective in the treatment of these cancers. Defactnib, which is being marketed by biopharmaceutical company Verastem, Inc.
Mesothelioma attacks the lining of the…
View On WordPress